NEW YORK, January 1, 2026, 03:10 ET — Market closed
- Intelligent Bio Solutions shares more than doubled in the last session before slipping in after-hours trade.
- Company announced a new manufacturing partnership and a $10 million private placement.
- Investors are watching deal close timing, dilution risk and margin targets tied to the new supplier.
Intelligent Bio Solutions Inc said late Wednesday it will raise about $10 million in a private placement, sending its shares lower in after-hours trading after a sharp rally earlier in the session.
The financing lands as the micro-cap medtech company pitches a faster path to scale for its fingerprint-based drug screening reader, with management pointing to lower production costs and higher profitability ahead of a planned U.S. market entry.
Private placements are a common funding route for small companies, but they can dilute existing shareholders — meaning each share represents a smaller slice of the business — when new stock and stock-linked securities are issued.
INBS shares closed up 132.4% at $9.53 on Dec. 31 after touching $12.94 intraday, then fell 13.6% to $8.23 in after-hours trading. Volume swelled to about 108 million shares, far above recent daily activity, data showed.
Earlier Wednesday, the company said it struck a manufacturing partnership with Syrma Johari MedTech to support and scale production of its Intelligent Fingerprinting Drug Screening Reader. It said the shift is expected to cut annual production costs by more than 40% and lift gross margin — profit after production costs — by about 20 percentage points versus its prior arrangement, while quadrupling manufacturing capacity and reducing reliance on a single supplier. “Partnering with Syrma Johari is a strategically significant milestone for our business,” said Callistus Sequeira, vice president of global quality and operations. GlobeNewswire
After the close, Intelligent Bio Solutions said it agreed with two healthcare-focused institutional investors to issue 2,298,850 shares (or pre-funded warrants) and two series of warrants tied to the same number of shares each, for expected gross proceeds of about $10 million. Warrants give the holder the right to buy stock later at a fixed price; the company set the exercise price at $4.10, and said the combined purchase price was $4.35 per share and accompanying warrants, in a deal it described as priced “at-the-market” under Nasdaq rules. GlobeNewswire
The placement price sits near the stock’s $4.10 close on Dec. 30, before the manufacturing news-driven surge, but it is about 54% below Wednesday’s regular-session close — a gap that often draws selling as investors handicap dilution.
In December, Nasdaq notified the company that its stock had failed to meet the exchange’s $1 minimum bid requirement, and the company enacted a 1-for-10 reverse stock split. It has until June 15, 2026 to regain compliance, a filing showed.
Investors will now look for confirmation that the financing closes on or about Jan. 2, as the company said, and for any follow-up disclosure around the timing of manufacturing transition and whether the promised cost savings flow through to reported margins.
U.S. stock markets are closed on Thursday for New Year’s Day and are scheduled to reopen for regular trading on Friday, Jan. 2.
